Veterans Administration Adds Fibromyalgia
Code to Schedule
for Rating Disabilities
Federal Register: June 17, 1999 (Volume 64, Number 116)
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 4
Schedule for Rating Disabilities; Fibromyalgia
AGENCY: Department of Veterans Affairs.
ACTION: Final rule.
SUMMARY: This document adopts as a final rule without
change an interim
final rule adding a diagnostic code and evaluation criteria for fibromyalgia to the Department of Veterans
Affairs' (VA's) Schedule for Rating Disabilities. The intended effect of this rule is to insure that veterans
diagnosed with this condition meet uniform criteria and receive consistent evaluations.
DATES: Effective Date: This final rule is effective
June 17, 1999.
The interim rule adopted as final by this document was effective May 7, 1996.
FOR FURTHER INFORMATION CONTACT: Audrey Tomlinson
Policy and Regulations Staff (211B), Compensation and Pension Service, Veterans Benefits Administration,
Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 273-7215.
SUPPLEMENTARY INFORMATION: On May 7, 1996, VA published
in the Federal
Register an interim final rule with request for comments (61 FR 20438). The rule added a diagnostic code,
5025, and evaluation criteria for fibromyalgia to the section of the VA Schedule for Rating Disabilities
(38 CFR part 4) that addresses the musculoskeletal system (38 CFR 4.71a). A 60-day comment period ended
July 8, 1996, and we received three comments, one from two physicians in the Department of Medicine at
The Oregon Health Sciences University, and two from VA employees.
The evaluation criteria for fibromyalgia under diagnostic
have one requisite that applies to all levels: ``[w]ith widespread musculoskeletal pain and tender points,
with or without associated fatigue, sleep disturbance, stiffness, paresthesias, headache, irritable bowel
symptoms, depression, anxiety, or Raynaud's-like symptoms.'' The 40-, 20-, and 10-percent evaluation levels
are additionally based on whether these findings are constant, or nearly so, and refractory to therapy;
are episodic, but present more than one-third of the time; or require continuous medication for control.
One commenter felt that the use of the phrase ``with or without'' as used in diagnostic code 5025 is confusing
and might be interpreted as rendering the symptoms that follow the phrase as superfluous and unnecessary
in the evaluation of fibromyalgia.
Some individuals with fibromyalgia have only pain
and tender points;
others have pain and tender points plus stiffness; still others have pain and tender points plus stiffness
and sleep disturbance; etc. As a shorter way of stating this, we have used the phrase ``with or without,''
followed by a list of symptoms, to indicate that any or all of these symptoms may be part of fibromyalgia,
but none of them is necessarily present in a particular case. When symptoms in addition to pain and tenderness
are present, they may be used as part of the assessment of whether fibromyalgia symptoms are episodic
or constant. When none of the symptoms on the list is present, the determination of whether the condition
is episodic or constant must be based solely on musculoskeletal pain and tender points. The term ``with
or without'' is also used in Sec. 4.116 (Schedule of ratings--gynecological conditions and disorders of
the breast) of the rating schedule under diagnostic code 7619, ``Ovary, removal of,'' where the criterion
for a zero-percent evaluation is ``removal of one with or without partial removal of the other.'' We believe
that in both cases the phrase ``with or without,'' rather than adding confusion, better defines the potential
scope of the condition under evaluation. We therefore make no change based on this comment.
The same commenter questioned whether the intent is
to place a ceiling
of 40 percent on the evaluation of fibromyalgia despite the presence of one or more of the symptoms following
the phrase ``with or without.''
As the evaluation criteria indicate, there may be
in fibromyalgia. If signs and symptoms due to fibromyalgia are present that are not sufficient to warrant
the diagnosis of a separate condition, they are evaluated together with the musculoskeletal pain and tender
points under the criteria in diagnostic code 5025 to determine the overall evaluation. The maximum schedular
evaluation for fibromyalgia in such cases is 40 percent. If, however, a separate disability is diagnosed,
e.g., dysthymic disorder, that is determined to be secondary to fibromyalgia, the secondary condition
can be separately evaluated (see 38 CFR 3.310(a)), as long as the same signs and symptoms are not used
to evaluate both the primary and the secondary condition (see 38 CFR 4.14 (Avoidance of pyramiding)).
In such cases, fibromyalgia and its complications may warrant a combined evaluation greater than 40 percent.
Since these rules are for general application, they need not be specifically referred to under diagnostic
Another commenter referred to a statement in the supplementary
to the interim final rule that indicated that fibromyalgia is a benign disease that does not result in
loss of musculoskeletal function. The commenter said that while it is not a malignant disease which leads
to anatomic crippling, the result of persistent chronic pain is often musculoskeletal dysfunction.
The statement regarding the lack of loss of musculoskeletal
is supported by medical texts which state, for example, that objective musculoskeletal function is not
impaired in fibromyalgia (``The Manual of Rheumatology and Outpatient Orthopedic Disorders'' 349 (Stephen
Padgett, Paul Pellicci, John F. Beary, III, eds., 3rd ed. 1993)); that the syndrome is not accompanied
by abnormalities that are visible, palpable, or measurable in any traditional sense; and that the patient
must recognize the physical benignity of the problem (``Clinical Rheumatology'' 315 (Gene V. Ball, M.D.
and William J. Koopman, M.D., 1986)). These medical texts confirm that fibromyalgia does not result in
objective musculoskeletal pathology. The criteria we have established to evaluate disability due to fibromyalgia
are therefore based on the symptoms of fibromyalgia rather than on objective loss of musculoskeletal function.
The same commenter said that more could have been said about the wide clinical spectrum of fibromyalgia
and the associated stress response which may lead to clinical problems of psychopathology, inappropriate
behavior, deconditioning, hormonal imbalance, and sleep disorder. The evaluation criteria do include a
broad spectrum of possible symptoms, and sleep disturbance is one of them. As discussed above, any disability,
including a mental disorder, that is medically determined to be secondary to fibromyalgia, can be separately
evaluated. The rating schedule is, however, a guide to the evaluation of disability for compensation,
not treatment (see 38 CFR 4.1), and it is unnecessary for that purpose to include a broad discussion of
the clinical aspects of fibromyalgia. We therefore make no change based on this comment.
The same commenter said that it is important to stress
may co-exist with other rheumatic disorders and have an additive effect on disability.
If two conditions affecting similar functions or anatomic
present, and one is service-connected and one is not (a situation that is not unique to rheumatic disorders),
the effects of each are separately evaluated, if feasible. When it is not possible to separate the effects
of the conditions, VA regulations at 38 CFR 3.102, which require that reasonable doubt on any issue be
resolved in the claimant's favor, dictate that the effects be attributed to the service-connected condition.
Since there is an established method of evaluating co-existing conditions, there is no need to stress
the point that other diseases may co-exist with fibromyalgia, resulting in additive effects, and we make
no change based on this comment.
The commenter also stated that the correct diagnosis
and the exclusion of other rheumatic conditions are of paramount importance in ensuring a successful treatment
The diagnosis of fibromyalgia and exclusion of other
are functions of the examiner and outside the scope of the rating schedule, which, as noted earlier, is
a guide for the evaluation of disability for purposes of compensation, not treatment. We therefore make
no change based on this comment.
One commenter stated that claimants with fibromyalgia
with limitation of motion of various joints of the body, and the rating agency will have to take into
consideration pain on movement and functional loss due to pain (see 38 CFR 4.40 and 4.45). The commenter
felt that the proposed scheme invites separate ratings for limitation of motion of each joint.
Fibromyalgia is a ``nonarticular'' rheumatic disease
Manual'' (1369, 16th ed. 1992)), and objective impairment of musculoskeletal function, including limitation
of motion of the joints, is not present, in contrast to the usual findings in ``articular'' rheumatic
diseases. Joint examinations in fibromyalgia are necessary only to exclude other rheumatic diseases because
physical signs other than tender points at specific locations are lacking. The pain of fibromyalgia is
not joint pain, but a deep aching, or sometimes burning pain, primarily in muscles, but sometimes in fascia,
ligaments, areas of tendon insertions, and other areas of connective tissue (Ball and Koopman, 315). The
evaluation criteria require that the pain be widespread, and that the symptoms be assessed based on whether
they are constant or episodic, or require continuous medication, but they are not based on evaluations
of individual joints or other specific parts of the musculoskeletal system. We believe the evaluation
criteria make clear the basis of evaluation, and we therefore make no change based on this comment.
Based on the rationale set forth in the interim final
and this document, we are adopting the provisions of the interim final rule as a final rule without change.
We also affirm the information in the interim final rule document concerning the Regulatory Flexibility
List of Subjects in 38 CFR Part 4
Disability benefits, Individuals with disabilities,
Accordingly, the interim final rule amending 38 CFR
part 4 which
was published at 61 FR 20438 on May 7, 1996, is adopted as a final rule without change.
Approved: March 24, 1999.
Togo D. West, Jr.,
[FR Doc. 99-15342 Filed 6-16-99; 8:45 am]
BILLING CODE 8320-01-P
The CFIDS Association of America
and Encouragement for the CFIDS Community
PO Box 220398
Charlotte NC 28222-0398
Info Line: 800/442-3437
Resource Line: 704/365-2343
General e-mail: email@example.com
© 2000, The CFIDS Association of America, Inc.
you have comments
about this website please contact firstname.lastname@example.org